

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Depui et al.
Serial No : TBA
Filed : TBA
For : ORAL PHARMACEUTICAL DOSAGE
FORMS COMPRISING A PROTON
PROTON PUMP INHIBITOR AND A NSAID
Examiner :
Group Art Unit : 1615

"Express Mail" Label No. ET537319873US

Date of Deposit **JULY 14, 2003**

I hereby certify that this paper is being deposited with
the United States Postal Service "Express Mail Post Office to
Addressee" service under 37 CFR §1.10 on the date indicated
above and is addressed to: MAIL STOP PATENT APPLICATION;
Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450.

Bernard Mays

(Type or print name of person mailing paper or fee)

Bernard Mays
Signature Date of Signature

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit this communication in compliance with 37 C.F.R. §§1.56, 1.97 and
1.98.

The referenced application is a continuation of U.S. Patent Application Serial No. 10/090,882 (the “‘882 application”), filed March 4, 2002, which is a continuation of U.S. Patent Application Serial No. 09/471,958, filed December 23, 1999 (the “‘958 application”), now US 6,365,184, issued April 2, 2002, which is a continuation of U.S. Patent Application Serial No. 08/793,078, filed February 13, 1997 (the “‘078 application”), abandoned, which was the National Stage of International Application No. PCT/SE96/01735, filed December 20, 1996.

The documents identified on the attached form PTO-1449 include the patents, publications and other information which were previously cited by or submitted to the Office in the great-grandparent ‘078 application, the grandparent '958 application, and the parent ‘882 application. Pursuant to C.F.R. §1.98(d), copies of the identified documents are not required in connection with this Information Disclosure Statement as copies were submitted or cited in the preceding ‘078, ‘958, and ‘882 applications and the present continuation application relies upon the earlier filing dates of the '078, '958, and '882 applications under 35 U.S.C. §120.

TIME OF TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed concurrently with a continuation application.

Applicants submit that no fee is required in connection with this submission. However, if any fee is due in connection with the communication, authorization is hereby given to charge Account No. 23-1703.

Dated: July 14, 2003

Respectfully submitted,

John M. Genova

John M. Genova
Reg. No. 32,224
Attorney for Applicants
Attorney Direct Dial: (212) 819-8832

Client No. 007470
(212) 819-8200

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
 (REV. 2-82) PATENT AND TRADEMARK OFFICE

Atty. Docket No.
1103326-0250

Serial No.
TBA

INFORMATION DISCLOSURE STATEMENT
 BY APPLICANT

Applicant:
Depui, et al.

Filing Date:
TBA

Group:
1615

UNITED STATES PATENT DOCUMENTS

*Examiner Initial	Document No.							Date	Name	Class	Sub-Class	Filing Date, if Appropriate
	4	7	8	6	5	0	5	11-88	Lovgren et al.	424	468	
	5	4	1	7	9	8	0	05/23/95	Goldman et al.	424	464	

FOREIGN PATENT DOCUMENTS

	Document No.							Date	Country	Class	Sub-Class	Translation Yes No
	0	0	7	2	0	2	1	08/82	EP			
	8	5	0	1	2	0	7	09/84	WO			
	0	5	8	7	2	2	0	08/93	EP			
	0	5	4	1	3	6	9	11/92	EP			
	2	2	8	5	9	8	9	01/95	GB			
	9	4	0	3	1	6	0	07/93	WO			
	0	6	4	8	4	8	7	10/94	EP			
	0	1	0	8	5	0	4	10/83	EP			
	8	5	0	3	4	3	6	02/85	WO			
	2	0	6	6	0	7	0	12/80	GB			
	2	1	3	2	8	8	7	11/83	GB			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

	McCarthy, D.M. 1989 Gastroenterology 96:662-674, "Nonsteroidal Antiinflammatory Drug-Induced Ulcers..."
--	---

Examiner: _____ Date Considered: _____

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 2-82)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Atty. Docket No. 1103326-0250	Serial No. TBA
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Depui, et al.	
		Filing Date: TBA	Group: 1615

UNITED STATES PATENT DOCUMENTS

*Examiner Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date, if Appropriate
	5 7 5 3 2 6 5	05/19/88	Bergstrand et al	424	474	

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-Class	Translation Yes No
	0 1 1 1 1 0 3	10/83	EP			
	0 0 8 0 3 4 1	11/82	EP			
	2 0 9 1 0 9 7	11/81	GB			
	0 1 7 0 7 5 2	12/84	EP			
	0 0 1 3 5 6 6	01/90	EP			
	0 1 0 8 2 9 5	10/83	EP			
	8 7 0 2 2 4 0	09/86	WO			
	9 3 1 2 7 7 2	12/92	WO			
	0 3 9 1 5 1 8	02/90	EP			
	0 0 0 8 7 8 0	08/79	EP			
	9 5 1 0 2 6 4	4/20/95	WO			X

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

	Walan, A. Et al. 1989 "Effect of omeprazole and ranitine on ulcer healing..." The N.E. J. Med 320:69.
--	--

Examiner: _____ Date Considered: _____

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609;
Draw line through citation if not in conformance and not considered. Include copy of this form with
next communication to applicant.

FORM PTO-1449 (REV. 2-82)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							Atty. Docket No. 1103326-0250	Serial No. TBA
INFORMATION DISCLOSURE STATEMENT BY APPLICANT								Applicant: Depui, et al.	
								Filing Date: TBA	Group: 1615

UNITED STATES PATENT DOCUMENTS

*Examiner Initial		Document No.				Date	Name	Class	Sub-Class	Filing Date, if Appropriate

FOREIGN PATENT DOCUMENTS

		Document No.							Date	Country	Class	Sub-Class	Translation Yes No
		9	7	2	5	0	6	4	7-97	WIPO			
		0	4	2	6	4	7	9	5-90	EP			
		0	2	4	7	9	8	3	12-87	EP			
		0	3	6	5	9	4	7	5-90	EP			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

		Guess, H.A. et al. 1988 "Fatal upper gastrointestinal hemorrhage or perforation..." J. Clin. Epidimol 41:35-45
		Larkai, E.N. et al. 1987 "Gastroduodenal mucosa and dyspeptic symptoms..." Am. J. Gastroenterology 82:1153
		Catford, J.C. et al. 1986 "Confidential inquiry into deaths from peptic ulcer..." Health Trends 18:37-41
		Hawkey C. "Non-steroidal anti-inflammatory drugs and peptic ulcers..." (1990) 300:278-284
		Scheiman, J.M. "Pathogenesis of gastroduodenal injury..." (1982) Semin. Arthritis Reheum. 21(4):201-210-
		Walan, A. Et al. 1989 "Effect of omeprazole and ranitine on ulcer healing..." The N.E. J. Med 320:69.

Examiner:

Date Considered:

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 2-82)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE								Atty. Docket No 1103326-0250	Serial No. TBA
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT								Applicant: Depui, et al.	
										Filing Date: TBA	Group: 1615

UNITED STATES PATENT DOCUMENTS

*Examiner Initial	Document No.							Date	Name	Class	Sub-Class	Filing Date, if Appropriate
	5	8	1	7	3	3	8	06.10.98	Bergstrand et al.	424	474	
	5	7	6	3	4	2	2	09.07.98	Lichtenberger et al	514	78	12.05.95
	5	9	5	5	4	5	1	21.09.99	Lichtenberger et al	514	78	24.09.96

FOREIGN PATENT DOCUMENTS

	Document No.							Date	Country	Class	Sub-Class	Translation Yes No
	9	8	2	2	1	1	7	28.05.98	WO			
	9	8	2	2	1	1	8	28.05.98	WO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

		Drug Facts and Comparisons 1994, pages 1679-1684
		Remington: The Science and Practice of Pharmacy, chapter 93, 1650-1656, 1995
		Wan, L.S.C., "A Multiple-unit Tablet Formulation for Multi-layer Drug-coated Granules", S.T.P. PHARMA SCIENCES, 4(5)(1994), PP-336-342.

Examiner:

Date Considered:

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 2-82)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE								Atty. Docket No. 1103326-0250-Con.	Serial No. TBA	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT										Applicant: Depui et al.	
										Filing Date: TBA	Group: 1615

UNITED STATES PATENT DOCUMENTS

*Examiner Initial		Document No.							Date	Name	Class	Sub-Class	Filing Date, if Appropriate
		6	3	6	5	1	8	4	4/2002	DePui, et al.			

FOREIGN PATENT DOCUMENTS

	Document No.									Date	Country	Class	Sub-Class	Translation Yes No
		0	2	2	2	1	0	8	21 Mar. 2002	WO				
		9	5	0	9	8	3	1	13 Apr. 1995	WO				
		9	5	3	0	6	4	1	16 Nov. 1995	WO				
		9	4	1	2	4	6	3	9 June 1994	WO				
		0	1	6	6	0	8	7	13 Sept. 2001	WO				
		9	4	0	4	4	8	4	3 Mar. 1994	WO				
0	8	-	3	0	1	7	6	3	19 Nov. 1996	JP			X	

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

	Chem. Pharm. Bull., 42(11), 2327-2331 (1994)
	Chem. Pharm. Bull., 44(7), 1361-1366 (1996)

Examiner: _____ Date Considered: _____

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.